ClinicalTrials.gov record
Completed Phase 1 Interventional

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

ClinicalTrials.gov ID: NCT03569280

Public ClinicalTrials.gov record NCT03569280. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 1:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Study identification

NCT ID
NCT03569280
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Enrollment
16 participants

Conditions and interventions

Interventions

  • Enzalutamide or Abiraterone or Apalutamid Combination Product

Combination Product

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 25, 2019
Primary completion
Jan 9, 2023
Completion
Jun 14, 2023
Last update posted
Jul 17, 2023

2019 – 2023

United States locations

U.S. sites
3
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89169
North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists Port Jefferson Station New York 11776
University of Virginia Cancer Center Charlottesville Virginia 22903

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03569280, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 17, 2023 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03569280 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →